Sr Director, US Medical Early Assets - Market Access

Sr Director, US Medical Early Assets
- Market Access

Are you ready to turn ideas into life-changing medicines? At AstraZeneca, we are committed to addressing the unmet needs of patients worldwide through scientific innovation. Reporting directly to the Executive Director, US Medical Early Asset Team Lead, you will be part of a team focused on the development of ambitious US medical strategies for our early pipeline. Youwillinfluence across a complexglobalmatrixto ensure USpayer, health-system, policy, and affordabilityneeds are integrated intoassetdevelopmentand investment decisions.

The Sr Director, US Medical Early Asset
- Market Access is the strategic lead for shaping the US access and value strategy for our BBU portfolio pipeline assets from late discovery through Phase 2. The Senior Director ensures that payer, health-system, policy, pricing, and affordability considerations are incorporated early into asset development, evidence generation, and investment decisions. Serving as the senior US access voice on cross-functional asset teams, the Senior Director provides clear, evidence-based recommendations that strengthen future differentiation, reimbursement, and patient access.

• US Value Strategy and TPP Input:
  Define US payer-relevant elements of the Target Product Profile (clinical endpoints, comparators, subpopulations, line of therapy) and shape differentiation claims that resonate with payers and health systems.
• Evidence and Study Design Influence:
  Provide US access input to clinical and RWE plans (endpoints, PROs, inclusion/exclusion, duration, head-to-heads, external controls) to support label, compendia, guideline inclusion, and payer coverage.
• Payer Value Proposition & Dossier Foundations:
  Lead early value story development (unmet need, clinical and economic value drivers), outline core claims, and define requirements for future AMCP dossier modules and global value dossiers.
• Early Pricing and Contracting Hypotheses:
  Develop US WAC/NET ranges, reference pricing considerations, budget impact boundaries, and contracting scenarios (e.g., outcomes-based, indication-based) with assumptions and risks.
• HEOR & RWE Strategy:
  Co-create early economic models and RWE plans (burden of illness, treatment patterns, comparative effectiveness, adherence/persistence) to support access and inform trial design.
• Access Policy and Channel Strategy:
  Assess policy landscape (Medicare, Medicaid, ACA, IRA/Part D redesign, 340B, state policies), site-of-care and channel dynamics (buy-and-bill, pharmacy benefit, specialty distribution), and implications for design and launch.
• Payer, IDN, and PBM Insights:
  Plan and synthesize early payer/IDN advisory input and rapid tests (concept reviews, value message testing, coverage criteria simulations) to de-risk access hurdles.
• Competitive and Class Access Analytics:
  
  Maintainlandscape of class coverage criteria, step/edit rules,utilization management, coding/reimbursement precedents;identify opportunities to differentiate andanticipatebarriers.
• Forecasting & Investment Support:
  Build access assumptions for early forecasts (gross-to-net, access mix, UM intensity, speed-to-coverage) and partner with Finance onrNPV/scenario analyses for governance.
• Governance and Cross-Functional Leadership:
  Represent US access in global/US asset teams and at governance gates (indicationsequencing, go/no-go, TPP approval), driving clear, evidence-backed recommendations.
• Compliance and Ethics:
  
  Operate within US promotional and pre-approval communication standards and company policies; ensure research and external interactions meet compliance requirements.

• Bachelor's degreein health economics, public health, pharmacy, life sciences, business, economics, or a related discipline;advanceddegreesuchasanMPH, MS,PharmD,PhD,orMBA strongly preferred.
• 8+yearsof progressive experienceinthe pharmaceutical, biotechnology, healthcare, payer,orconsultingenvironment,includingsubstantialexperience inUSMarket
  
  Access,HEOR,pricing and reimbursement, orearlyassetstrategy.
• Profiles,clinicaldevelopmentplans,evidencestrategies,andassetinvestmentdecisions.
• DeepunderstandingoftheUSpayerandhealthsystemenvironment,includingcommercialandgovernmentpayers,medicalandpharmacybenefit dynamics, pricing and reimbursement,utilization management, distribution and site-of-care considerations, and relevant policy trends.
• StrongunderstandingofHEOR,realworldevidence,payerresearch,economicmodeling,andvalueproposition…